Delivery Order SPE2DB22D2206-SPE2DB24FHH04
- Not listed
- This federal contract award, valued at $17,487.74, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a prescription medication. This contract is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November...
- This federal contract award, valued at $7,736.74, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a medical product, with a completion date of January 29, 2025. The contract is a firm fixed-price arrangement with no set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite...
- This federal contract award, valued at $12,127.40, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under Amerisourcebergen's Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and...
- This federal contract award, valued at $26,537.85, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a medical product. The contract has a Firm Fixed Price pricing type and an ultimate completion date of November 26, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $46,654.32, is a delivery order for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The contract has an ultimate completion date of April 3, 2025 and is a firm fixed-price contract. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,885.36, is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The contract has an ultimate completion date of January 9, 2024 and is a Firm Fixed Price Delivery Order. This award is part of a larger Indefinite Delivery Contract (IDC) that...
- This federal contract award is a delivery order valued at $9,654.66 with an ultimate completion date of March 21, 2025. The award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a medical product. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order worth $8,852.69 for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The contract has a period of performance through May 21, 2024 and is a Firm Fixed Price type. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the...
- This federal contract award, valued at $28,739.04, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product, with a completion date of January 7, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at...
- This federal contract award, issued by the Defense Logistics Agency (DLA), was granted to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $74,846.30, is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB24FHH04Delivery Order
This federal contract award, valued at $7,501.44, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a medical product, to support federal healthcare programs. The contract is a Firm Fixed Price Delivery Order with a completion date of May 21, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.5k | 5/20/24 |